These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1491741)

  • 1. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography.
    Nordberg A; Lilja A; Lundqvist H; Hartvig P; Amberla K; Viitanen M; Warpman U; Johansson M; Hellström-Lindahl E; Bjurling P
    Neurobiol Aging; 1992; 13(6):747-58. PubMed ID: 1491741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.
    Nordberg A; Lundqvist H; Hartvig P; Andersson J; Johansson M; Hellstrŏm-Lindahi E; Långström B
    Dement Geriatr Cogn Disord; 1997; 8(2):78-84. PubMed ID: 9065319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical studies in Alzheimer patients with positron emission tomography.
    Nordberg A
    Behav Brain Res; 1993 Nov; 57(2):215-24. PubMed ID: 7906947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET.
    Nordberg A
    Acta Neurol Scand Suppl; 1993; 149():62-5. PubMed ID: 8128843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities.
    Nordberg A; Amberla K; Shigeta M; Lundqvist H; Viitanen M; Hellström-Lindahl E; Johansson M; Andersson J; Hartvig P; Lilja A; Långström B; Winblad B
    Alzheimer Dis Assoc Disord; 1998 Sep; 12(3):228-37. PubMed ID: 9772028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo detection of neurotransmitter changes in Alzheimer's disease.
    Nordberg A
    Ann N Y Acad Sci; 1993 Sep; 695():27-33. PubMed ID: 7902055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
    Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET studies and cholinergic therapy in Alzheimer's disease.
    Nordberg A
    Rev Neurol (Paris); 1999; 155 Suppl 4():S53-63. PubMed ID: 10637939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains--in vivo assessment using positron emission tomography.
    Nordberg A; Lundqvist H; Hartvig P; Lilja A; Långström B
    Alzheimer Dis Assoc Disord; 1995; 9(1):21-7. PubMed ID: 7605618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo PET study of cerebral [11C] methyl- tetrahydroaminoacridine distribution and kinetics in healthy human subjects.
    Traykov L; Tavitian B; Jobert A; Boller F; Forette F; Crouzel C; Di Giamberardino L; Pappata S
    Eur J Neurol; 1999 May; 6(3):273-8. PubMed ID: 10210906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease.
    McGeer PL; Kamo H; Harrop R; Li DK; Tuokko H; McGeer EG; Adam MJ; Ammann W; Beattie BL; Calne DB
    CMAJ; 1986 Mar; 134(6):597-607. PubMed ID: 3512063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia.
    Weinberger DR; Jones D; Reba RC; Mann U; Coppola R; Gibson R; Gorey J; Braun A; Chase TN
    J Neuropsychiatry Clin Neurosci; 1992; 4(3):239-48. PubMed ID: 1498576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ST09, a Novel Thioester Derivative of Tacrine, Alleviates Cognitive Deficits and Enhances Glucose Metabolism in Vascular Dementia Rats.
    Liu JM; Wu PF; Rao J; Zhou J; Shen ZC; Luo H; Huang JG; Liang X; Long LH; Xie QG; Jiang FC; Wang F; Chen JG
    CNS Neurosci Ther; 2016 Mar; 22(3):220-9. PubMed ID: 26813743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease.
    Kadir A; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2006 Nov; 188(4):509-20. PubMed ID: 16832659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease as measured using positron emission tomography.
    Foster NL; VanDerSpek AF; Aldrich MS; Berent S; Hichwa RH; Sackellares JC; Gilman S; Agranoff BW
    J Cereb Blood Flow Metab; 1987 Aug; 7(4):415-20. PubMed ID: 3497161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy.
    Kumlien E; Hartvig P; Valind S; Oye I; Tedroff J; Långström B
    Epilepsia; 1999 Jan; 40(1):30-7. PubMed ID: 9924899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography in Alzheimer's disease.
    Duara R; Grady C; Haxby J; Sundaram M; Cutler NR; Heston L; Moore A; Schlageter N; Larson S; Rapoport SI
    Neurology; 1986 Jul; 36(7):879-87. PubMed ID: 3487046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional cerebral glucose transport and utilization in Alzheimer's disease.
    Friedland RP; Jagust WJ; Huesman RH; Koss E; Knittel B; Mathis CA; Ober BA; Mazoyer BM; Budinger TF
    Neurology; 1989 Nov; 39(11):1427-34. PubMed ID: 2812318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.